Zydus Lifesciences Expands US Portfolio with Contrast Agent Agreement

Zydus Lifesciences, a leading global healthcare company, has solidified its presence in the US market through a strategic partnership with Viwit Pharmaceuticals. The agreement grants Zydus exclusive rights to market, distribute, and sell generic versions of GADAVIST™ (gadobutrol injection) and DOTAREM® (gadoterate meglumine injection) in the United States.

Viwit will be responsible for the development, manufacturing, and regulatory submissions for these essential MRI contrast agents. Once approved, Zydus will leverage its strong market presence and commercial expertise to bring these products to US healthcare providers. The addition of gadobutrol and gadoterate meglumine to Zydus’ injectable portfolio marks a significant milestone in its commitment to providing innovative healthcare solutions.

The combined US market potential for these contrast agents is estimated to be approximately $237 million, underscoring the substantial commercial opportunity for Zydus. This strategic partnership aligns with the company’s broader goal of expanding its reach in the US market and delivering high-quality, affordable healthcare options to patients.

About Zydus Lifesciences Ltd

Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. 

About Viwit Pharmaceuticals 

Viwit is an innovation-driven biopharmaceutical and healthcare company with integrated research and development, production and marketing systems. Viwit is committed to building a platform for pharmaceutical innovation and commercialisation and establishing an ecosystem that serves the healthcare needs of the general public.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.